Cancers of the central nervous system remain to be the grande challenge in cancer therapy. The aiPTO team has developed clinically validated predictive patient avatar models and trained generative AI models capable of predicting patient responses. With these disruptive technologies, aiPTO Techbio is dedicated to revolutionizing the CNS cancer R&D ecosystem and ultimately providing effective therapeutics to CNS cancer patients.
Avarta & AI
Next-Gen Patient Avatar Features histopathology and molecular pathology indistinguishable from patient tumors.Predicts patient responses validated by a prospective clinical study.Fully compatible with drug R&D and personalized therapies (chemo, radio, immunetherapy, targeted and combo).
Generative AI Model Predicts patient responses to drug treatments.Provides FIC drug targets for aiPTO-based pipeline development.Predicts and identify solutions overcome drug resistance.